



Pulmatrix Appoints John P. Hanrahan Chief Medical Officer

Lexington, Mass. – September 18th, 2008 – Pulmatrix Inc., a biotechnology company commercializing a broad new class of treatments for respiratory disease, announced today the appointment of John P. Hanrahan, M.D., M.P.H., as Senior Vice President and Chief Medical Officer. Dr. Hanrahan will lead the Company's clinical development programs beginning with Phase II trials assessing the efficacy of Pulmatrix's lead product in the treatment and prevention of several different respiratory infectious diseases.

Dr. Hanrahan joins Pulmatrix from Sepracor where he most recently served as Executive Medical Director for Pulmonary products. During his six years with Sepracor he led clinical development activities for the asthma drug Levalbuterol and the COPD drug Arformoterol, through FDA approvals in 2005 and 2006 respectively. Dr. Hanrahan's responsibilities at Sepracor included leading worldwide clinical development of the entire portfolio of projects for pulmonary and internal medicine indications, and serving on the Respiratory and Internal Medicine Therapeutic Assessment teams in support of partnering and M&A activities. Prior to joining Sepracor, he held multiple leadership positions spanning clinical development and medical affairs at Boehringer-Ingelheim and Muro Pharmaceuticals. Dr. Hanrahan began his career at Harvard Medical School as a full-time tenure-track faculty member in pulmonary and emergency medicine and researcher in pulmonary epidemiology, while holding corresponding hospital appointments at the Beth Israel Deaconess Medical Center.

Dr. Hanrahan commented, "Pulmatrix's innovative therapies show revolutionary promise to meaningfully impact the transmission and occurrence of respiratory infections. I am truly excited to join the team and help guide the clinical development programs."

Pulmatrix Chief Executive Officer Bob Connelly added, "This Company could fundamentally alter the therapeutic landscape for many respiratory diseases, and offer practical options to treat and prevent infection by a wide array of airborne pathogens. John comes to us at a perfect time with an ideal background in pulmonary medicine and public health, combined with a successful track record of advancing respiratory products through the clinic."

About Pulmatrix

Pulmatrix is a clinical stage biotechnology company developing a new class of inhaled therapies that treat, prevent, and help control the spread of respiratory infectious disease. The Company's novel pathogen independent approach utilizes the inherent properties of the airway and immune system to enable a single affordable product to combat a broad spectrum of viral and bacterial infections, without the development of resistance. The Pulmatrix approach is based on the ground-breaking scientific work of renowned Harvard Professor David Edwards, and is financed by leading life science investors Polaris Venture Partners and 5AM Ventures.

Contact:
Sarah Mees
978-208-1499
sarah@kmcpartners.com